Skip to main content
Dupixent 200 mg/1.14mL injection, solution by Sanofi-Aventis U.S. LLC
Dupixent, 200 mg/1.14mL, injection, solution Drug class: Interleukin-4 Receptor alpha Antagonist. Available on prescription only. Listed by Sanofi-Aventis U.S. LLC.
Prescription only

Dupixent

Dupilumab

Listed by Sanofi-Aventis U.S. LLC

Strength
200 mg/1.14mL
Form
Injection, Solution
Route
Subcutaneous
Class
Interleukin-4 Receptor alpha Antagonist

What it contains

  • Dupilumab 200 mg/1.14mL

FDA record

Dosage form Injection, Solution
Route Subcutaneous
Drug class Interleukin-4 Receptor alpha Antagonist
Approval route BLA — biologic licence
NDC code 0024-5919
FDA application BLA761055
RxNorm concept 1876401
Package sizes listed 2
Marketed since June 2021

Other products containing Dupilumab

See all

Same active ingredient, different manufacturer, strength or form. Products matching on both ingredient and strength are usually interchangeable — but confirm before switching, especially with modified-release forms.

Dupixent

Dupilumab

Strength
300 mg/2mL
Form
Injection, Solution
Class
Interleukin-4 Receptor alpha Antagonist
Rx only

Sanofi-Aventis U.S. LLC

Not stocked by us — reference only

Dupixent

Dupilumab

Strength
300 mg/2mL
Form
Injection, Solution
Class
Interleukin-4 Receptor alpha Antagonist
Rx only

Sanofi-Aventis U.S. LLC

Not stocked by us — reference only

Dupixent

Dupilumab

Strength
200 mg/1.14mL
Form
Injection, Solution
Class
Interleukin-4 Receptor alpha Antagonist
Rx only

Sanofi-Aventis U.S. LLC

Not stocked by us — reference only

Information only, not medical advice. Nothing on this page indicates that a medication is safe or suitable for you. Speak to a prescriber or pharmacist before starting, stopping or switching any medicine.